Dock Line
The Hamon Biomedical and Simmons Research buildings on the north campus of UT Southwestern Medical Center in Dallas, photographed July 17, 2019
The Hamon Biomedical and Simmons Research buildings on UT Southwestern's north campus in Dallas, photographed July 17, 2019. This is not a picture of the pregnenolone study or its participants. A Nov. 18 university release describes a small trial of the hormone in women with depression. (Nightryder84)

Jane Long

November 19, 2026 · 3 min read

UT Southwestern Study Finds Pregnenolone May Alter Brain Circuits Tied to Depression

A Nov. 18 UT Southwestern release says a small, short trial found that 500 milligrams a day of pregnenolone changed communication between brain regions involved in depression and cognitive control.

UT Southwestern Medical Center researchers reported Nov. 18 that pregnenolone, a naturally occurring steroid hormone the body produces from cholesterol, may change how key brain regions involved in depression and cognitive control communicate with one another.

The university release describes a study, conducted with the UT Dallas Center for BrainHealth and published in the Journal of Clinical Psychiatry, that could help researchers develop a brain-based marker of how neurosteroids affect the brain. The authors are careful not to present the work as a proven treatment. The next steps, the release says, are to test whether the observed brain-circuit changes are tied to improvement in depressive symptoms or cognition, and to try to replicate the findings in a larger sample.

"Previous studies have suggested that pregnenolone could be an effective treatment for depression in people with bipolar disorder, but we lacked insight into exactly how it affects neural circuits across the brain, especially those involved in depression," said corresponding author E. Sherwood Brown, M.D., Ph.D., M.B.A., professor of psychiatry in the Peter O'Donnell Jr. Brain Institute at UT Southwestern, vice chair for clinical research in the Department of Psychiatry, and director of the Psychoneuroendocrine Research Program. "These findings bring us one step closer to developing proven neuroimaging biomarkers that would enable us to see exactly how pregnenolone changes functional connectivity between regions of the brain in people with depression – and how we might shape those changes to benefit patients."

The study followed 29 women with mild to moderate major depressive disorder in a double-blind, placebo-controlled crossover trial. Participants received three seven-day treatment conditions — 500 or 800 milligrams per day of pregnenolone, or a placebo — taken by mouth. Researchers used blood tests and functional MRI, a technique that studies brain activity by measuring changes in blood flow and oxygen levels. The final fMRI analysis included 11 participants who had usable data from all three treatments.

Compared with the placebo, participants taking 500 milligrams a day had reduced functional connectivity between the amygdala and the left frontal pole, regions involved in emotional processing and cognitive control. The university said that change may reflect improved emotional regulation, a process often impaired in people with depression, and that the findings may help explain how pregnenolone and related neurosteroids could have an antidepressant effect. The connectivity change was seen with the 500-milligram dose but not the 800-milligram dose, which the researchers said suggests that more pregnenolone does not necessarily produce a greater effect on these circuits.

Both doses were well tolerated, with no serious adverse events reported, according to the release. Blood tests also showed that both doses significantly increased levels of allopregnanolone, a downstream neurosteroid involved in regulating brain signaling.

"This study gives us a better understanding of how neurosteroids may influence brain connectivity in women with depression, an area that hasn't been studied enough," said contributing author Francesca Filbey, Ph.D., deputy director at the UT Dallas Center for BrainHealth and the Bert Moore Endowed Chair and professor in the School of Behavioral and Brain Sciences at UT Dallas.

"Ultimately, the goal is to establish whether pregnenolone or related compounds can provide a clinically meaningful treatment option," Brown said. "These findings open the door to future research to determine whether these brain changes ultimately translate into meaningful improvements for patients with depression."

Other UT Southwestern Department of Psychiatry contributors named in the release are Elena Ivleva, M.D., Ph.D., professor; Jayme M. Palka, Ph.D., assistant professor; Zena Patel, M.P.A.S., PA-C.; and Traci Holmes, B.S., research programs manager. The study was funded through a grant from the National Center for Complementary and Integrative Health of the National Institutes of Health (R61AT009625).

The results come from a small, short trial in women only, with usable brain-imaging data from 11 people. They do not show that pregnenolone is an approved or established treatment for major depression, and they do not show that the circuit changes found at the 500-milligram dose improved patients' symptoms. Those questions, the researchers said, remain for later work.